Possible serotonergic mechanisms underlying the antidepressant and anti-obsessive-compulsive disorder responses

Biological Psychiatry

Volumn 44, Issue 5, 1998, Pages 313-323

  Blier, Pierre ^a   De Montigny, Claude ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Autoreceptors; Monoamine oxidase inhibitors; Pindolol; Serotonin reuptake inhibitors; Tricyclics

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; 5 METHOXYTRYPTAMINE; BUSPIRONE; CLORGYLINE; METERGOLINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; PINDOLOL; RITANSERIN; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG MECHANISM; NONHUMAN; OBSESSION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; RECEPTOR DOWN REGULATION; SEROTONIN RELEASE; SEROTONINERGIC SYSTEM; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031685344     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(98)00114-0     Document Type: Review

References (61)

1. Artigas F., Perez V., Alvarez E. Pindolol induces a rapid improvement of depressed patients with serotonin reuptake inhibitors. Arch Gen Psychiatry. 51:1994;248-251.
2. Barr L.C., Goodman W.K., Anand A., McDougle C.J., Price L.H. Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. Am J Psychiatry. 154:1997;1293-1295.
3. Benkelfat C., Murphy D.L., Zohar J., Hill J.L., Grover G., Insel T.R. Clomipramine in obsessive-compulsive disorder Further evidence for a serotonergic mechanism of action . Arch Gen Psychiatry. 46:1989;23-28.
4. Bergqvist PBF, Bouchard C, Blier P (1998): Effect of long-term administration of antidepressant treatments on serotonin release in brain regions involved in obsessive compulsive disorder. Biol Psychiatry (in press).
5. Berman R.M., Darnell A.M., Miller H.L., Anand A., Charney D.S. Effect of pindolol in hastening response to fluoxetine in the treatment of major depression A double-blind, placebo-controlled trial . Am J Psychiatry. 154:1997;37-43.
6. Blier P., Bergeron R. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J Clin Psychopharmacol. 15:1995;217-222.
7. Blier P., Bouchard C. Modulation of 5-HT release in the guinea-pig brain following long-term administration of antidepressant drugs. Br J Pharmacol. 113:1994;485-495.
8. Blier P., de Montigny C. Serotonergic but not noradrenergic neurons in rat CNS adapt to long-term treatment with monoamine oxidase inhibitors. Neuroscience. 16:1985;949-955.
9. 1A agonist gepirone Electrophysiological studies in the rat brain . Synapse. 1:1987;470-480.
10. Blier P., de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol Sci. 15:1994;220-226.
11. Blier P., de Montigny C., Azzaro A.J. Modification of serotonergic and noradrenergic neurotransmission by repeated administration of monoamine oxidase inhibitors Electrophysiological studies in the rat CNS . J Pharmacol Exp Ther. 227:1986;987-994.
12. 1A receptors without altering 5-HT autoreceptor sensitivity An electrophysiological study in the rat brain . Synapse. 1:1987;225-232.
13. Blier P., Chaput Y., de Montigny C. Long-term 5-HT reuptake blockade, but not monoamine oxidase inhibition, decreases the function of terminal 5-HT autoreceptors An electrophysiological study in the rat brain . Naunyn Schmiedebergs Arch Pharmacol. 337:1988;246-254.
14. 1A receptors in the dorsal raphe and hippocampus I - Effect of spiperone . J Pharmacol Exp Ther. 265:1993;7-15.
15. 1A receptors produces a rapid antidepressant response. Neuropsychopharmacology. 16:1997;333-338.
16. 2A receptor antagonist, directly activates postsynaptic 5-HT inhibitory responses in the rat cerebral cortex. Naunyn Schmiedebergs Arch Pharmacol. 352:1995;283-290.
17. Chaput Y., de Montigny C., Blier P. Effect of a selective 5-HT reuptake blocker, citalopram, on the sensitivity of 5-HT autoreceptors Electrophysiological studies in the rat . Naunyn Schmiedebergs Arch Pharmacol. 333:1986;342-348.
18. Chaput Y., de Montigny C., Blier P. Presynaptic and postsynaptic modifications of the serotonin system by long-term antidepressant treatments Electrophysiological studies in the rat brain . Neuropsychopharmacology. 5:1991;219-229.
19. Charney D.S., Heninger G.R., Sternberg D.E. Serotonin function and mechanism of action of antidepressant treatment. Effects of amitriptyline and desipramine. Arch Gen Psychiatry. 41:1984;359-365.
20. Delgado P.L. Are there differences between the role of monoamine systems in the pathophysiology of depression and the mechanisms of antidepressant drug action Evidence from neurotransmitter depletion studies . Eur J Neuropsychopharmacol. 7:(suppl 2):1997;577.
21. Delgado P.L., Charney D.S., Price L.H., Aghajanian G.K., Landis H., Heninger G.R. Serotonin function and the mechanism of antidepressant action Reversal of antidepressant induced remission by rapid depletion of plasma tryptophan . Arch Gen Psychiatry. 47:1990;411-418.
22. de Montigny C. Electroconvulsive treatments enhance responsiveness of forebrain neurons to serotonin. J Pharmacol Exp Ther. 228:1984;230-234.
23. de Montigny C. Lithium addition in treatment-resistant depression. Int Clin Psychopharmacol. 9:(suppl 2):1994;31-35.
24. de Montigny C., Aghajanian G.K. Tricyclic antidepressants Long-term treatment increases responsivity of rat forebrain neurons to serotonin . Science. 202:1978;1303-1306.
25. El Mansari M., Blier P. In vivo electrophysiological characterization of 5-HT receptors in the guinea pig head of caudate nucleus and orbitofrontal cortex. Neuropharmacology. 36:1997;577-588.
26. El Mansari M., Blier P. Effect of a prolonged paroxetine treatment on the responsiveness of postsynaptic 5-HT receptors in the rat orbitofrontal cortex. Soc Neurosci. 23:1997;386.4.
27. El Mansari M., Bouchard C., Blier P. Alteration of serotonin release in the guinea pig orbitofrontal cortex Relevance to the treatment of obsessive compulsive disorder . Neuropsychopharmacology. 13:1995;117-127.
28. 2 receptor and fluvoxamine effect in obsessive-compulsive disorder. Hum Psychopharmacol. 7:1992;287-289.
29. Goodman W.K., Price L.H., Rasmussen S.A., Delgado P.L., Heninger G.R., Charney D.S. Efficacy of fluvoxamine in obsessive-compulsive disorder A double-blind comparison with placebo . Arch Gen Psychiatry. 46:1989;36-44.
30. Greenberg B., Benjamin J., Murphy D. Metergoline biphasically enhances, then antagonizes, fluxoxetine's therapeutic effects in obsessive-compulsive disorder. Neuropsychopharmacology. 10:1994;265S.
31. Greist J., Chouinard G., DuBoff E., Halaris A., Won Kim S., Koran L., et al. Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry. 52:1995;289-295.
32. 1A receptors. Soc Neurosci. 23:1997;385.8.
33. Hanes K.R. Serotonin, psilocybin, and body dysmorphic disorder A case report . J Clin Psychopharmacol. 16:1996;188-189.
34. Hyttel J. Citalopram - Pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Prog Neuropsychopharmacol Biol Psychiatry. 6:1982;277-295.
35. Insel T.R. Toward a neuroanatomy of obsessive-compulsive disorder. Arch General Psychiatry. 49:1992;739-744.
36. Jenike M.A. Obsessive-compulsive disorder Efficacy of specific treatments as assessed by controlled trials . Psychopharmacol Bull. 29:1993;487-499.
37. Leonard H.L., Swedo S.E., Lenane M.C., Rapoport J.L. A double-blind desipramine substitution during long-term clomipramine treatment in children and adolescents with obsessive compulsive disorder. Arch Gen Psychiatry. 48:1991;922-927.
38. Mann J.J., Fox Aarrons S., Wilner P.J. A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. Arch Gen Psychiatry. 46:1989;45-53.
39. McCall R.B., Aghajanian G.K. Serotonergic facilitation of facial motoneuron excitation. Brain Res. 169:1979;11-27.
40. McDougle C.J., Goodman W.K., Leckman J.F., Holzer J.C., Barr L.C., McCance-Katz, et al. Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychiatry. 150:1993;647-649.
41. Menkes D.B., Aghajanian G.K., McCall R.B. Chronic antidepressant treatment enhances α-adrenergic and serotonergic responses in the facial nucleus. Life Sci. 27:1980;45-55.
42. Miller H.L., Delgado P.L., Salomon R.M., Berman R., Krystal J.H., Heninger G.R., et al. Clinical and biochemical effects of catecholamine depletion on antidepressant-induced remission of depression. Arch Gen Psychiatry. 53:1996;117-128.
43. Montgomery S.A. Pharmacological treatment of obsessive-compulsive disorder. Hollander E., Zohar J., Marazziti D., Olivier B. Current Insights in Obsessive Disorder. 1994;215-226 Wiley, New York.
44. Moreno F.A., Delgado P.L. Hallucinogen-induced relief of obsessions and compulsions. Am J Psychiatry. 145:1997;1037-1038.
45. Moret C., Briley M. Serotonin autoreceptor subsensitivity and antidepressant activity. Eur J Pharmacol. 1980:1990;351-356.
46. Nishizawa S., Benkelfat C., Young S.N., Leyton M., Mzengeza S., de Montigny C., et al. Differences between males and females in rates of serotonin synthesis in human brain. Proc Natl Acad Sci USA. 94:1997;5308-5315.
47. Pérez V., Gilaberte I., Faries D., Alvarez E., Artigas F. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet. 349:1997;1594-1597.
48. Pigott T.A., L'Heureux F., Hill J.L., Bihari K., Bernstein S.E., Murphy D.L. A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder. J Clin Psychopharmacol. 12:1992;11-18.
49. Piñeyro G., Blier P., Dennis T., de Montigny C., Blier P. Desensitization of the neuronal 5-HT carrier following its long-term blockade. J Neurosci. 14:1994;3036-3047.
50. 1D receptors regulate 5-HT release in the rat raphe nuclei In vivo voltammetry and in vitro superfusion studies . Neuropsychopharmacology. 13:1995;249-260.
51. 1B/1D receptors in the modulation of 5-hydroxytryptamine levels in the frontal cortex of the conscious guinea pig. Eur J Pharmacol. 326:1997;23-30.
52. Robinson D.S., Rickel K., Feighner J. Clinical effects of the 5-HT-1A partial agonists in depression A composite analysis of buspirone in the treatment of depression . J Clin Psychopharmacol. 10:1990;675-765.
53. 1A receptors In vivo microdialysis and electrophysiological studies in the rat brain . Neuropsychopharmacology. 15:1996;349-360.
54. 1A agonist BIMT 17 Differential efficacy at pre- vs postsynaptic areas in the rat brain . Soc Neurosci Abstr. 23:1997;111.0.
55. 1D (BRL-15572) receptor ligands on guinea-pig and human 5-HT auto- and heteroreceptors. Naunyn Schmiedebergs Arch Pharmacol. 356:1997;321-327.
56. Thomas P., Bordet R., Thomas C.E., Alexandre J.Y., Chatteau J., Cyran C., et al. Pindolol addition shortens delay of action of paroxetine in major depression A double blind controlled trial . Eur Neuropsychopharmacol. 7:(suppl 2):1997;173.
57. Tollefson G.D., Ramprey A.M., Potvin J.H., Henike M.A., Rush A.J., Dominquez R.A., et al. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry. 51:1994;559-576.
58. Tome M.B., Isaac M.T., Harte R., Holland C. Paroxetine and pindolol A randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency . Int Clin Psychopharmacol. 12:1997;81-89.
59. Wilcox C.S., Ferguson J.M., Dale J.L., Heiser J.F. A double-blind trial of low- and high-dose ranges of gepirone-ER compared with placebo in the treatment of depressed outpatients. Psychopharmacol Bull. 32:1996;335-342.
60. Wilkinson L.O., Auerbach S.B., Jacobs B.L. Extracellular serotonin levels change with behavioral state but not pyrogen-induced hyperthermia. J Neurosci. 11:1991;2732-2741.
61. Zanardi R., Artigas F., Sforzini L., Gasperini M., Smeraldi E., Perez J. How long should pindolol be associated to paroxetine to improve the antidepressant response? J Clin Psychopharmacol. 17:1997;446-450.